Genovate Biotechnology Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Chia-Chen Chu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years
Mar 09
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?
Feb 10Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 08CEO
Chia-Chen Chu
no data
Tenure
Chia-Chen Chu is General Manager & Director of Genovate Biotechnology Co., Ltd.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CSO | no data | no data | 0.21% NT$ 4.8m | |
| General Manager & Director | no data | no data | no data | |
| Supervisor | no data | no data | no data | |
| Supervisor | 18.4yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 1.7yrs | no data | no data | |
| Representative Director | 1.7yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Representative Director | 1.7yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
1.7yrs
Average Tenure
Experienced Board: 4130's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 19:38 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genovate Biotechnology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |